top of page
Black-Blue Logo.png

News

Amicrobe, Inc., Developer of Novel Synthetic Biologics, Adds Fifth U.S. Patent to Intellectual Property Portfolio

Today, Amicrobe, Inc. announced the issue of U.S. Patent No. 11,285,189, entitled "Compositions and uses of locally applied antimicrobials with enhanced performance and safety." Amicidins are synthetic biologics designed to be safe for individuals and the environment – this new patent acknowledges the Company's inventive approach in achieving this important goal. Amicrobe's fifth U.S. patent brings its intellectual property portfolio to 26 issued / allowed patents worldwide, further protecting its Amicidin technology platform and innovative product candidates.  The full press release can be viewed here.

3142 Tiger Run Court - Suite 101, Carlsbad, California 92010

+1 (888) 490-1180

Macro Biologics, Inc.

bottom of page